Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:SWTX

SpringWorks Therapeutics (SWTX) Stock Price, News & Analysis

SpringWorks Therapeutics logo

About SpringWorks Therapeutics Stock (NASDAQ:SWTX)

Advanced Chart

Key Stats

Today's Range
$46.99
$46.99
50-Day Range
$46.46
$46.99
52-Week Range
$28.21
$62.00
Volume
N/A
Average Volume
2.66 million shs
Market Capitalization
$3.54 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$52.57
Consensus Rating
Hold

Company Overview

SpringWorks Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
8th Percentile Overall Score

SWTX MarketRank™: 

SpringWorks Therapeutics scored higher than 8% of companies evaluated by MarketBeat, and ranked 922nd out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    SpringWorks Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on 1 buy rating, 7 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    SpringWorks Therapeutics has received no research coverage in the past 90 days.

  • Read more about SpringWorks Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for SpringWorks Therapeutics are expected to grow in the coming year, from ($2.05) to ($0.13) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of SpringWorks Therapeutics is -13.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of SpringWorks Therapeutics is -13.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    SpringWorks Therapeutics has a P/B Ratio of 7.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for SWTX.
  • Dividend Yield

    SpringWorks Therapeutics does not currently pay a dividend.

  • Dividend Growth

    SpringWorks Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for SWTX.
  • MarketBeat Follows

    1 people have added SpringWorks Therapeutics to their MarketBeat watchlist in the last 30 days.
Receive SWTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SpringWorks Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SWTX Stock News Headlines

BREAKING: The House just passed 3 pro-crypto bills!
THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. tc pixel
See More Headlines

SWTX Stock Analysis - Frequently Asked Questions

SpringWorks Therapeutics (NASDAQ:SWTX) announced its quarterly earnings results on Friday, May, 9th. The company reported ($1.11) EPS for the quarter, missing analysts' consensus estimates of ($0.81) by $0.30. The company earned $49.09 million during the quarter, compared to analyst estimates of $64.19 million. SpringWorks Therapeutics had a negative net margin of 115.60% and a negative trailing twelve-month return on equity of 51.10%.

SpringWorks Therapeutics subsidiaries include SpringWorks Subsidiary 1 Inc, SpringWorks Subsidiary 2 Inc, SpringWorks Subsidiary 3 Inc, SpringWorks Subsidiary 4 Inc, SpringWorks Therapeutics LLC, and SpringWorks Therapeutics Operating Company Inc..

SpringWorks Therapeutics (SWTX) raised $126 million in an IPO on Friday, September 13th 2019. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. ​J.P. Morgan, Goldman Sachs and Cowen​ ​ served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

SpringWorks Therapeutics' top institutional shareholders include State Street Corp (3.97%), Beryl Capital Management LLC (2.81%), Magnetar Financial LLC (2.72%) and Norges Bank (2.41%). Insiders that own company stock include Orbimed Advisors Llc, Saqib Islam, Badreddin Edris, Daniel Lynch, Bhavesh Ashar, Daniel Pichl and Julie Hambleton.
View institutional ownership trends
.

Based on aggregate information from My MarketBeat watchlists, some other companies that SpringWorks Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

Last Earnings
5/09/2025
Today
8/27/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SWTX
CIK
1773427
Fax
N/A
Employees
230
Year Founded
2017

Price Target and Rating

High Price Target
$68.00
Low Price Target
$47.00
Potential Upside/Downside
+11.9%
Consensus Rating
Hold
Rating Score (0-4)
2.13
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.41)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$258.13 million
Net Margins
-115.60%
Pretax Margin
-115.60%
Return on Equity
-51.10%
Return on Assets
-43.80%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.33
Quick Ratio
4.18

Sales & Book Value

Annual Sales
$191.59 million
Price / Sales
18.48
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.47 per share
Price / Book
7.26

Miscellaneous

Outstanding Shares
75,350,000
Free Float
69,449,000
Market Cap
$3.54 billion
Optionable
Optionable
Beta
0.68

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:SWTX) was last updated on 8/27/2025 by MarketBeat.com Staff
From Our Partners